Thermo Fisher Scientific Inc. (NYSE:TMO)

Thermo Fisher Scientific Inc. experienced fluctuating financial performance between 2021 and 2025. While overall revenues increased, profitability metrics exhibited periods of decline and subsequent recovery. A significant shift occurred in the revenue mix, with service revenues growing substantially while product revenues decreased initially before stabilizing.

Revenue Analysis

Total revenues increased from US$39.211 billion in 2021 to US$44.556 billion in 2025, representing a cumulative growth of approximately 13.6%. However, this growth was not linear. Product revenues declined from US$30.361 billion in 2021 to US$25.034 billion in 2023 before showing modest recovery to US$25.964 billion in 2025. Service revenues demonstrated consistent growth, increasing from US$8.850 billion in 2021 to US$18.592 billion in 2025, more than doubling over the period. This indicates a strategic shift towards higher-margin service offerings.

Profitability Analysis

Gross profit decreased from US$19.638 billion in 2021 to US$17.100 billion in 2023, coinciding with the decline in product revenues and rising costs of revenues. It then recovered to US$18.238 billion in 2025. Operating income followed a similar pattern, decreasing from US$10.028 billion in 2021 to US$6.859 billion in 2023, and then increasing to US$7.746 billion in 2025. Net income attributable to Thermo Fisher Scientific Inc. decreased from US$7.725 billion in 2021 to US$5.995 billion in 2023, before recovering to US$6.704 billion in 2025.

Cost Structure

Cost of revenues increased significantly from US$19.573 billion in 2021 to US$26.318 billion in 2025. Both cost of product revenues and cost of service revenues contributed to this increase, with the latter experiencing a more substantial percentage increase. Selling, general and administrative expenses remained relatively stable, with a gradual increase from US$8.007 billion in 2021 to US$8.732 billion in 2025. Research and development expenses also remained relatively consistent throughout the period.

Financial Income/Expense

Interest expense increased substantially from US$536 million in 2021 to US$1.419 billion in 2025, while interest income also increased, but at a slower rate. Other income (expense) remained relatively small and fluctuated. The provision for income taxes decreased in 2022 and 2023, then increased in 2024 and 2025, aligning with changes in income before income taxes.

Restructuring and Other Costs

Restructuring and other costs decreased from US$197 million in 2021 to US$114 million in 2022, but then increased significantly to US$459 million in 2023, before decreasing to US$363 million in 2025. These fluctuations suggest potential strategic adjustments or one-time events impacting these costs.

In summary, the period examined demonstrates a company adapting to changing market conditions. The growth in service revenues partially offset the decline in product revenues, and while profitability experienced a dip in 2023, it showed signs of recovery by 2025. Increased interest expense warrants monitoring, as does the continued growth in the cost of revenues.